Betamethasone Benzoate

CHEMBL1200376 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
496.6 g/mol
LogP
3.9
Phase
4

An ester form of betamethasone formulated for topical use to treat inflammatory skin conditions such as eczema and psoriasis. It reduces redness, itching, and swelling by suppressing local immune responses in the skin. Prolonged application to large skin areas or under occlusion increases the risk of systemic absorption.

Молекулярная масса

496,6000 g/mol

LogP

3,90

TPSA

101,00 Ų

Правило пяти Липинского

Соответствует

Механизм действия

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO

InChI

InChI=1S/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1

Molecular Formula

C29H33FO6

HBD / HBA

2 / 7

Вращаемые Связи

5

Тяжёлые Атомы

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

An ester form of betamethasone formulated for topical use to treat inflammatory skin conditions such as eczema and psoriasis. It reduces redness, itching, and swelling by suppressing local immune responses in the skin. Prolonged application to large skin areas or under occlusion increases the risk of systemic absorption.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Betamethasone Benzoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200376. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5282492. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.